Stock listing

NASDAQ:OLMA Olema Pharmaceuticals, Inc. Stock

Home listing (NASDAQ) of Olema Pharmaceuticals, Inc.

Follow Olema Pharmaceuticals, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:OLMA

$7.02 USD -0.04 (-0.6%)

Close on Nov 20, 2026

Past year -68.1% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$6.88 – $7.35 USDNov 20, 2026
Volume
1.26M sharesNov 20, 2026
Market cap
$615.0M USDAt the close on Nov 20, 2026 · price × 87.61M shares outstanding
52-week range
$6.24 – $36.26 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$10.34M USDMedian day 1.12M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Olema Pharmaceuticals, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:OLMA · Home$7.02 USD-0.04 (-0.6%)1,256,470$7.01$7.35$6.88$7.06Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:OLMA · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$7.02-0.04-0.6%$7.01$7.35$6.881,256,470
$7.06-0.16-2.2%$7.235$7.50$7.0551,177,860
$7.22-0.14-1.9%$7.36$7.50$7.021,266,249
$7.36-0.20-2.6%$7.48$7.73$7.081,524,472
$7.56+0.04+0.5%$7.44$7.86$7.181,696,513
$7.52-0.52-6.5%$7.88$8.02$7.451,996,916
$8.04+0.77+10.6%$7.29$8.25$7.071,819,444
$7.27-0.09-1.2%$7.28$7.595$7.00935,308
$7.36+0.03+0.4%$7.50$7.545$7.101,516,460
$7.33+0.57+8.4%$6.80$7.35$6.7351,337,270
$6.76-0.78-10.3%$7.49$7.52$6.711,703,998
$7.54+0.19+2.6%$7.60$7.62$7.281,091,000
$7.35+0.28+4.0%$7.12$7.41$7.001,207,346
$7.07+0.07+1.0%$7.00$7.13$6.711,118,784
$7.00-0.33-4.5%$7.22$7.42$6.92751,077
$7.33-0.16-2.1%$7.47$7.59$7.141,153,497
$7.49+0.45+6.4%$6.93$7.49$6.811,437,507
$7.04+0.42+6.3%$6.62$7.13$6.492,190,088
$6.62+0.21+3.3%$6.44$6.78$6.341,987,370
$6.41-0.61-8.7%$6.93$6.94$6.2351,984,600
$7.02-0.03-0.4%$6.96$7.10$6.831,064,900
$7.05-0.20-2.8%$7.24$7.47$7.031,236,200
$7.25+0.14+2.0%$7.12$7.61$7.0851,871,500
$7.11+0.53+8.1%$6.68$7.255$6.681,272,600
$6.58-0.29-4.2%$6.83$6.83$6.481,081,300
$6.87+0.07+1.0%$6.84$6.945$6.701,088,400
$6.80-0.22-3.1%$6.92$7.15$6.611,845,300
$7.02-0.34-4.6%$7.30$7.363$6.992,013,800
$7.36-0.46-5.9%$7.77$7.77$7.331,018,700
$7.820.000.0%$7.77$8.00$7.725758,200
$7.82-0.12-1.5%$7.87$8.21$7.561,400,200
$7.94+0.02+0.3%$7.90$8.23$7.79819,200
$7.92-0.33-4.0%$8.28$8.29$7.801,038,900
$8.25+0.025+0.3%$8.28$8.30$7.851,006,100
$8.225-0.045-0.5%$8.39$8.52$8.101,071,900
$8.27-0.37-4.3%$8.58$8.66$8.191,009,500
$8.64+0.10+1.2%$8.59$8.86$8.421,542,800
$8.54-0.07-0.8%$8.60$8.73$8.461,079,600
$8.61-0.14-1.6%$8.71$8.85$8.40979,200
$8.75-0.29-3.2%$9.04$9.04$8.571,382,700
$9.04+0.21+2.4%$8.79$9.27$8.591,486,100
$8.83-0.81-8.4%$9.64$9.64$8.701,642,200
$9.64+0.01+0.1%$9.66$9.815$9.561,490,500
$9.63-0.19-1.9%$9.95$10.13$9.611,069,600
$9.82-0.08-0.8%$9.88$9.93$9.753,061,400
$9.90+0.17+1.7%$9.89$10.35$9.731,087,900
$9.73-0.05-0.5%$9.86$9.93$9.441,246,300
$9.78-0.51-5.0%$10.29$10.34$9.651,733,100
$10.29+0.07+0.7%$9.99$10.37$9.791,822,800
$10.22-0.47-4.4%$10.79$10.86$10.181,013,500
$10.69+0.33+3.2%$10.19$10.98$10.111,116,300
$10.36-0.625-5.7%$11.13$11.18$10.35863,400
$10.99+0.235+2.2%$10.61$11.06$10.46736,700
$10.75+0.02+0.2%$10.61$10.85$10.57505,300
$10.73-0.10-0.9%$10.71$10.98$10.58773,300
$10.83+0.27+2.6%$10.58$11.02$10.48866,400
$10.56+0.13+1.2%$10.36$10.63$10.28766,100
$10.43+0.16+1.6%$10.20$10.53$10.09937,000
$10.27-0.52-4.8%$10.69$10.77$10.19740,800
$10.79-0.06-0.6%$10.70$10.92$10.62383,300
$10.85-0.06-0.5%$10.78$10.97$10.58471,900
$10.91+0.48+4.6%$10.60$11.02$10.60799,924
$10.43-0.26-2.4%$10.58$10.62$10.29727,325
$10.69-0.21-1.9%$10.90$11.24$10.65748,500
$10.90-0.41-3.6%$11.10$11.12$10.671,039,100
Ticker
NASDAQ:OLMA
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Olema Pharmaceuticals, Inc. news

Olema Pharmaceuticals, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
23 in the last 12 months · 122 in all · newest Nov 18, 2026 · oldest 2020
Decks
14 decks · latest August 2026

Where Olema Pharmaceuticals, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:OLMA · Home listing · This pageNASDAQUnited StatesUSD
BOATS:OLMABOATSUnited StatesUSD

Valuation

Price/book 1.7× against a median of 4.1×: 2nd lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$204.6M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
1.7×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
1.25

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Olema Pharmaceuticals, Inc. · NASDAQ:OLMAUS$615.0MUS$204.6Mn/an/an/a1.7×n/a0.0×1.25
Shouyao Holdings Beijing Co. Ltd. Class A · SSE:688197US$648.7MUS$566.3Mn/a37.8×n/a6.8×−18.6%0.0×n/a
Prime Medicine, Inc. · NASDAQ:PRMEUS$645.8MUS$695.1Mn/a98.4×n/a76.5×n/a13.1×2.28
Sagimet Biosciences Inc. - Series A · NASDAQ:SGMTUS$638.7MUS$404.3Mn/an/an/a2.6×n/a0.0×1.96
Gubra A/S · OMXCOP:GUBRAUS$638.5MUS$533.6M2.6×1.4×1.7×4.2×64.1%0.2×n/a
Kura Oncology, Inc. · NASDAQ:KURAUS$634.9MUS$152.6Mn/a1.9×n/a35.4×−369.3%0.6×1.30
Alphamab Oncology · HKEX:9966US$628.9MUS$454.4Mn/a5.5×n/a2.5×−20.1%0.2×n/a
Iambic Therapeutics, Inc. · NASDAQ:IAMUS$621.4MUS$369.4Mn/a39.2×n/an/a−820.0%n/an/a
Janux Therapeutics, Inc. · NASDAQ:JANXUS$616.7M−US$308.6Mn/a−13.3×n/a0.7×−428.7%0.0×0.95
Alebund Pharmaceuticals (Jiangsu) Limited Class H · HKEX:9637US$608.9MUS$483.3Mn/a105×n/a2.9×n/a0.4×n/a
Annexon, Inc. · NASDAQ:ANNXUS$587.7MUS$423.7Mn/an/an/a4.1×n/a0.3×1.63
Median of the othersUS$631.9MUS$439.0M2.6×21.6×1.7×4.1×−194.7%0.2×1.63

Forecasts

9 strong buy · 2 buy · 1 hold · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.

Price target
36.00 USD · Analysts' mean
EPS, year to Dec 2026
-2.53 · 9 analysts

Team and board

Officers

OfficerRole
Sean P. BohenPresident and CEO
Jason V. O'ByrneChief Financial Officer
James WagnerVice President, Legal Counsel
Shawnte M. MitchellChief Legal Officer and Corporate Secretary
Courtney O'KonekVice President, Corporate Communications
Amoli PandyaVice President, Corporate Law
Angelos DovletoglouSenior Vice President, CMC and Supply Chain
Ganesh WaghmareVice President, Drug Safety and Pharmacovigilance
Gopinath PalanisamyVice President, Pre-Clinical Pharmacology and Toxicology
Julie DexterSenior Vice President, People and Culture
Kamesh KuchimanchiSenior Vice President, Regulatory Affairs
Karen PaeseVice President, Supply Chain
Kristin BrosofskyVice President, Clinical Operations
Margaret TondaVice President, Clinical Science
Mark ShilkrutSenior Vice President, Clinical Development
Meghna ChowdarySenior Vice President, Commercial Strategy and Operations
Rachel WeiVice President, Biostatistics
Radha IyerVice President, Quality Assurance
Richard HernandezSenior Vice President, Clinical Operations
Ronald E. SavageVice President, Clinical Pharmacology
Yolande Du ToitVice President, Medical Affairs
David C. MylesChief Scientific Officer
Naseem ZojwallaChief Medical Officer

Board

DirectorRole
Angelos DovletoglouSenior Vice President, CMC and Supply Chain
Courtney O'KonekVice President, Corporate Communications
David C. MylesChief Scientific Officer
Ganesh WaghmareVice President, Drug Safety and Pharmacovigilance
Gopinath PalanisamyVice President, Pre-Clinical Pharmacology and Toxicology
James WagnerVice President, Legal Counsel
Jason V. O'ByrneChief Financial Officer
Julie DexterSenior Vice President, People and Culture
Kamesh KuchimanchiSenior Vice President, Regulatory Affairs
Karen PaeseVice President, Supply Chain
Kristin BrosofskyVice President, Clinical Operations
Margaret TondaVice President, Clinical Science
Mark ShilkrutSenior Vice President, Clinical Development
Meghna ChowdarySenior Vice President, Commercial Strategy and Operations
Naseem ZojwallaChief Medical Officer
Prakash RamanDirector
Radha IyerVice President, Quality Assurance
Richard HernandezSenior Vice President, Clinical Operations
Ronald E. SavageVice President, Clinical Pharmacology
Sean P. BohenPresident and CEO
Shawnte M. MitchellChief Legal Officer and Corporate Secretary
Yolande Du ToitVice President, Medical Affairs

Events

QuarterResultsShare move
Q3 2026Nov 10, 2026 · Before open−1.2%
Q2 2026Aug 10, 2026 · After close−12.7%
Q1 2026May 12, 2026 · Before open−6.0%
Q4 2025Mar 2, 2026−3.2%
Q3 2025Nov 10, 2025 · Before open+4.2%
Q2 2025Aug 11, 2025 · After close+16.2%
Q1 2025May 13, 2025 · After close−3.9%
Q4 2024Mar 10, 2025 · Before open−4.1%
Q3 2024Nov 12, 2024 · After close−0.5%
Q2 2024Aug 6, 2024 · After close−9.9%
All 20 quarters
QuarterResultsShare move
Q1 2024May 8, 2024 · After close−9.3%
Q4 2023Mar 11, 2024 · After close−6.6%
Q3 2023Nov 7, 2023 · After close+3.1%
Q2 2023Aug 8, 2023 · After close+12.1%
Q1 2023May 9, 2023 · After close−8.7%
Q4 2022Mar 9, 2023 · After close+3.5%
Q3 2022Nov 8, 2022 · After close−5.1%
Q2 2022Aug 9, 2022 · After close−26.7%
Q1 2022May 9, 2022 · After close+6.8%
Q4 2021Feb 28, 2022 · After close+15.0%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (August 2026)Investor deck40 slidesAugust 2026
Investor Presentation (January 2026)Investor deck39 slidesJan 12, 2026
Investor Presentation (October 2025)Investor deck39 slidesOct 20, 2025
Investor Presentation (August 2025)Investor deck37 slidesAug 11, 2025
Investor Presentation (March 2025)Investor deck32 slidesMar 5, 2025
Investor Presentation (January 2025)Investor deck34 slidesJan 13, 2025
SABCS 2024Conference18 slidesDec 10, 2024
Investor Presentation (September 2024)Investor deck30 slidesSep 27, 2024
ESMO Breast Cancer 2024Conference19 slidesMay 15, 2024
JP Morgan Conference January 2024Conference28 slidesJan 8, 2024
All 14 decks
DeckKindSlidesDate
San Antonio Breast Cancer Symposium (SABCS) 2023Conference32 slidesDec 6, 2023
ESMO 2023Conference27 slidesOct 23, 2023
Investor Presentation (May 2023)Investor deck37 slidesMay 11, 2023
Investor Presentation (November 2022)Investor deck36 slidesNovember 2022

Open Decks

Financings

RaiseDate
Public offering of common stock
Closed: US$218.5M raised · US$19 a share · TD Cowen +5
Dealers: TD Cowen (lead), Evercore ISI (co-lead), Guggenheim Securities (co-lead), LifeSci Capital (co-lead), Oppenheimer & Co. (co-lead), H.C. Wainwright & Co. (co-lead)
Nov 20, 2025
Private placement of common stock and pre-funded warrants
Announced: about US$250M · US$9.08 a share · Jefferies +6
Dealers: Jefferies (lead), J.P. Morgan, Goldman Sachs & Co. LLC, Citigroup, LifeSci Capital, Oppenheimer & Co., H.C. Wainwright & Co.
Buyers: Adage Capital Partners LP; Bain Capital Life Sciences; BVF Partners L.P.; Driehaus Capital Management; Janus Henderson Investors; Paradigm BioCapital Advisors; Wellington Management; Woodline Partners LP
Use of proceeds: Fund the OPERA-02 trial, the Phase 1/2 study of OP-3136, the ongoing Phase 3 OPERA-01 trial, working capital and general corporate purposes
Dec 2, 2024

Open Financings · Read by 6ix AI from the company's releases

IPO

Went public as Olema Pharmaceuticals, Inc. Priced at US$19.00 a share on Nov 18, 2020.

Price
US$19.00 a share
Shares offered
11,000,000 shares of common stock
Offering size
US$209 million
Underwriters' option
Up to 1,650,000 more shares
Listing
OLMA on the Nasdaq Global Select Market
Underwriters
J.P. Morgan, Jefferies, Cowen, Canaccord Genuity · In the order on the cover
Shares delivered
On or about Nov 23, 2020

Steps

StepWhen
Draft sent to the SEC in confidenceSep 21, 2020
Filed publiclyOct 30, 2020
Amended onceNov 16, 2020
Shares registered with an exchangeNov 17, 2020
Declared effective by the SECNov 18, 2020
Final prospectus, with the priceNov 19, 2020

Open IPO · From the cover of the final prospectus (424B4) filed Nov 19, 2020

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue00000000
Cost of revenue393.0K377.0K1.66M1.66M11.0K9.03K8.24K
Gross profit-393.0K-377.0K-1.66M-1.66M-11.0K-9.03K-8.24K
Research and development157.7M124.5M86.1M82.3M51.1M13.7M3.92M1.69M
Selling, general and administrative21.0M17.7M18.8M24.7M20.4M7.82M403.0K386.0K
Operating income-178.7M-142.3M-105.0M-107.0M-71.5M-21.5M-4.32M-2.08M
Depreciation and amortization490.0K393.0K377.0K357.0K163.0K11.0K9.00K8.00K
EBITDA-178.2M-141.9M-104.6M-106.6M-71.3M-21.5M-4.31M-2.07M
Interest expense357.0K232.0K653.0K028.0K
Income before tax-162.4M-129.5M-96.7M-104.8M-71.1M-22.1M-4.32M-2.20M
Income tax3.00K2.00K2.00K1.00K-210.0K642.0K-155.9K-90.0K
Net income-162.5M-129.5M-96.7M-104.8M-71.1M-22.1M-4.32M-2.20M
Earnings per share, basic-1.87-2.20-2.14-2.62-1.80-3.42-1.66-0.16
Earnings per share, diluted-1.87-2.20-2.14-2.62-1.80-3.42-1.66

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash and equivalents48.3M139.5M68.5M23.7M13.8M338.5M68.0K3.15M
Short-term investments457.1M294.6M193.3M180.7M273.4M0
Receivables4.06M2.12M673.0K319.0K130.0K
Inventory-4.02M-319.0K-353.0K
Current assets515.5M438.5M266.5M208.9M290.7M342.1M103.0K3.24M
Property, plant and equipment274.0K746.0K968.0K1.48M1.47M75.0K26.0K26.0K
Total assets533.4M451.0M276.9M215.6M295.9M342.7M132.0K3.27M
Accounts payable9.25M4.46M2.70M374.0K23.0K719.0K935.0K116.0K
Current liabilities51.8M41.8M21.6M16.5M9.02M4.58M1.38M201.0K
Long-term debt3.00M
Total debt1.19M1.43M2.42M2.56M3.29M
Total liabilities54.9M42.0M23.1M18.1M11.4M4.58M10.7M9.55M
Shareholders' equity478.6M409.0M253.9M197.5M284.6M338.1M-10.6M-6.28M
Shares outstanding81.4M74.3M55.0M40.3M39.8M39.3M40.3M14.1M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash from operations-146.7M-104.4M-83.7M-82.1M-50.7M-19.9M-3.08M-2.18M
Capital spending0-159.0K0-363.0K-1.57M-56.0K-56.0K-56.0K
Free cash flow-146.7M-104.5M-83.7M-82.4M-52.3M-19.9M-3.08M-2.18M
Cash from investing-155.8M-93.5M-4.85M91.5M-275.4M-56.0K-56.0K-56.0K
Cash from financing211.3M268.8M133.4M476.0K1.39M358.4M358.4M5.25M
Dividends paid-3.09M
Share buybacks1.03M476.0K1.39M-2.29M00
Change in cash-91.2M70.9M44.8M9.89M-324.7M338.5M-3.08M3.08M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
8-K · Current reportNov 12, 2026Current reportSEC
10-Q · Quarterly reportNov 10, 2026Quarterly reportSEC
8-K · Current reportNov 10, 2026ResultsSEC
SCHEDULE 13D/A · Big-stake notice, amendedOct 16, 2026Big-stake noticeSEC
8-K · Current reportOct 15, 2026Management or board changeSEC
4 · Change in ownershipSep 2, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 13, 2026Insider tradeSEC
8-K · Current reportAug 13, 2026Management or board changeSEC
10-Q · Quarterly reportAug 10, 2026Quarterly reportSEC
Show 200 filings
FilingDateTypeFiled with
8-K · Current reportAug 10, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 6, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 29, 2026Big-stake noticeSEC
4 · Change in ownershipJul 27, 2026Insider tradeSEC
144 · Notice of proposed saleJul 24, 2026Other filingsSEC
144 · Notice of proposed saleJul 23, 2026Other filingsSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
8-K · Current reportJun 23, 2026Meeting outcomeSEC
8-K · Current reportMay 26, 2026Current reportSEC
8-K · Current reportMay 21, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
10-Q · Quarterly reportMay 12, 2026Quarterly reportSEC
8-K · Current reportMay 12, 2026ResultsSEC
8-K · Current reportMay 1, 2026Material contractSEC
4 · Change in ownershipApr 29, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 29, 2026Insider tradeSEC
ARS · Annual report to shareholdersApr 29, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 29, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 29, 2026Meeting noticeSEC
8-K · Current reportApr 29, 2026Management or board changeSEC
SCHEDULE 13G · Big-stake noticeMar 20, 2026Big-stake noticeSEC
144 · Notice of proposed saleMar 16, 2026Other filingsSEC
144 · Notice of proposed saleMar 16, 2026Other filingsSEC
S-8 · Registration statement for employee plansMar 16, 2026Offer documentSEC
10-K · Annual reportMar 16, 2026Annual reportSEC
8-K · Current reportMar 16, 2026ResultsSEC
144 · Notice of proposed saleMar 11, 2026Other filingsSEC
144 · Notice of proposed saleMar 10, 2026Other filingsSEC
144 · Notice of proposed saleMar 9, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 6, 2026Big-stake noticeSEC
4 · Change in ownershipMar 5, 2026Insider tradeSEC
144 · Notice of proposed saleMar 4, 2026Other filingsSEC
144 · Notice of proposed saleMar 4, 2026Other filingsSEC
144 · Notice of proposed saleMar 3, 2026Other filingsSEC
144 · Notice of proposed saleFeb 27, 2026Other filingsSEC
144 · Notice of proposed saleFeb 24, 2026Other filingsSEC
144 · Notice of proposed saleFeb 23, 2026Other filingsSEC
144 · Notice of proposed saleFeb 23, 2026Other filingsSEC
4 · Change in ownershipFeb 17, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 17, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 13, 2026Big-stake noticeSEC
144 · Notice of proposed saleFeb 12, 2026Other filingsSEC
SCHEDULE 13G · Big-stake noticeFeb 5, 2026Big-stake noticeSEC
4 · Change in ownershipFeb 4, 2026Insider tradeSEC
4 · Change in ownershipFeb 4, 2026Insider tradeSEC
4 · Change in ownershipFeb 4, 2026Insider tradeSEC
4 · Change in ownershipFeb 4, 2026Insider tradeSEC
8-K · Current reportJan 30, 2026Management or board changeSEC
4 · Change in ownershipJan 21, 2026Insider tradeSEC
144 · Notice of proposed saleJan 20, 2026Other filingsSEC
4 · Change in ownershipJan 16, 2026Insider tradeSEC
4 · Change in ownershipJan 15, 2026Insider tradeSEC
144 · Notice of proposed saleJan 15, 2026Other filingsSEC
4 · Change in ownershipJan 14, 2026Insider tradeSEC
144 · Notice of proposed saleJan 14, 2026Other filingsSEC
144 · Notice of proposed saleJan 14, 2026Other filingsSEC
144 · Notice of proposed saleJan 13, 2026Other filingsSEC
144 · Notice of proposed saleJan 13, 2026Other filingsSEC
8-K · Current reportJan 12, 2026ResultsSEC
144 · Notice of proposed saleJan 12, 2026Other filingsSEC
4 · Change in ownershipDec 30, 2025Insider tradeSEC
4 · Change in ownershipDec 29, 2025Insider tradeSEC
4 · Change in ownershipDec 23, 2025Insider tradeSEC
4 · Change in ownershipDec 23, 2025Insider tradeSEC
4 · Change in ownershipDec 23, 2025Insider tradeSEC
144 · Notice of proposed saleDec 23, 2025Other filingsSEC
144 · Notice of proposed saleDec 22, 2025Other filingsSEC
144 · Notice of proposed saleDec 22, 2025Other filingsSEC
144 · Notice of proposed saleDec 19, 2025Other filingsSEC
144 · Notice of proposed saleDec 19, 2025Other filingsSEC
144 · Notice of proposed saleDec 19, 2025Other filingsSEC
S-3ASR · Registration statementDec 11, 2025Offer documentSEC
4 · Change in ownershipDec 9, 2025Insider tradeSEC
4 · Change in ownershipDec 1, 2025Insider tradeSEC
4 · Change in ownershipNov 25, 2025Insider tradeSEC
8-K · Current reportNov 19, 2025Current reportSEC
424B5 · ProspectusNov 19, 2025Offer documentSEC
S-3MEFNov 18, 2025Other filingsSEC
424B5 · ProspectusNov 18, 2025Offer documentSEC
8-K · Current reportNov 18, 2025Current reportSEC
SCHEDULE 13G · Big-stake noticeNov 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportNov 10, 2025Quarterly reportSEC
8-K · Current reportNov 10, 2025ResultsSEC
8-K · Current reportOct 20, 2025Current reportSEC
4 · Change in ownershipSep 18, 2025Insider tradeSEC
144 · Notice of proposed saleSep 18, 2025Other filingsSEC
144 · Notice of proposed saleSep 16, 2025Other filingsSEC
8-K · Current reportSep 2, 2025Current reportSEC
10-Q · Quarterly reportAug 11, 2025Quarterly reportSEC
8-K · Current reportAug 11, 2025ResultsSEC
4 · Change in ownershipJun 13, 2025Insider tradeSEC
4 · Change in ownershipJun 13, 2025Insider tradeSEC
4 · Change in ownershipJun 13, 2025Insider tradeSEC
4 · Change in ownershipJun 13, 2025Insider tradeSEC
4 · Change in ownershipJun 13, 2025Insider tradeSEC
4 · Change in ownershipJun 13, 2025Insider tradeSEC
4 · Change in ownershipJun 13, 2025Insider tradeSEC
4 · Change in ownershipJun 13, 2025Insider tradeSEC
4 · Change in ownershipJun 13, 2025Insider tradeSEC
4 · Change in ownershipJun 13, 2025Insider tradeSEC
8-K · Current reportJun 13, 2025Meeting outcomeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedMay 13, 2025Big-stake noticeSEC
4/A · Change in ownership, amendedMay 13, 2025Insider tradeSEC
10-Q · Quarterly reportMay 13, 2025Quarterly reportSEC
8-K · Current reportMay 13, 2025ResultsSEC
ARS · Annual report to shareholdersApr 28, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 28, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 28, 2025Meeting noticeSEC
S-8 · Registration statement for employee plansMar 18, 2025Offer documentSEC
10-K · Annual reportMar 18, 2025Annual reportSEC
8-K · Current reportMar 18, 2025ResultsSEC
8-K · Current reportMar 5, 2025Current reportSEC
4 · Change in ownershipMar 3, 2025Insider tradeSEC
4 · Change in ownershipMar 3, 2025Insider tradeSEC
4 · Change in ownershipMar 3, 2025Insider tradeSEC
4 · Change in ownershipMar 3, 2025Insider tradeSEC
4 · Change in ownershipMar 3, 2025Insider tradeSEC
3 · Initial statement of ownershipFeb 28, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
EFFECT · Notice that a registration is effectiveJan 16, 2025Other filingsSEC
EFFECT · Notice that a registration is effectiveJan 16, 2025Other filingsSEC
424B5 · ProspectusJan 15, 2025Offer documentSEC
424B3 · ProspectusJan 15, 2025Offer documentSEC
4 · Change in ownershipJan 14, 2025Insider tradeSEC
4 · Change in ownershipJan 13, 2025Insider tradeSEC
3 · Initial statement of ownershipJan 13, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 13, 2025Big-stake noticeSEC
CORRESP · Letter to the SECJan 13, 2025Other filingsSEC
CORRESP · Letter to the SECJan 13, 2025Other filingsSEC
8-K · Current reportJan 13, 2025Current reportSEC
8-K · Current reportJan 10, 2025FinancingSEC
UPLOAD · Letter from the SECJan 8, 2025Other filingsSEC
UPLOAD · Letter from the SECJan 8, 2025Other filingsSEC
S-3 · Registration statementJan 6, 2025Offer documentSEC
S-3 · Registration statementJan 3, 2025Offer documentSEC
4/A · Change in ownership, amendedDec 18, 2024Insider tradeSEC
4 · Change in ownershipDec 17, 2024Insider tradeSEC
4 · Change in ownershipDec 17, 2024Insider tradeSEC
144 · Notice of proposed saleDec 13, 2024Other filingsSEC
4 · Change in ownershipDec 11, 2024Insider tradeSEC
4 · Change in ownershipDec 11, 2024Insider tradeSEC
4 · Change in ownershipDec 11, 2024Insider tradeSEC
4 · Change in ownershipDec 11, 2024Insider tradeSEC
4 · Change in ownershipDec 11, 2024Insider tradeSEC
DDec 11, 2024Other filingsSEC
144 · Notice of proposed saleDec 11, 2024Other filingsSEC
144 · Notice of proposed saleDec 11, 2024Other filingsSEC
144 · Notice of proposed saleDec 11, 2024Other filingsSEC
144 · Notice of proposed saleDec 11, 2024Other filingsSEC
SC 13G · Big-stake noticeDec 11, 2024Big-stake noticeSEC
144 · Notice of proposed saleDec 11, 2024Other filingsSEC
144 · Notice of proposed saleDec 10, 2024Other filingsSEC
144 · Notice of proposed saleDec 10, 2024Other filingsSEC
144 · Notice of proposed saleDec 10, 2024Other filingsSEC
144 · Notice of proposed saleDec 10, 2024Other filingsSEC
144 · Notice of proposed saleDec 10, 2024Other filingsSEC
8-K · Current reportDec 10, 2024Current reportSEC
4 · Change in ownershipDec 4, 2024Insider tradeSEC
SC 13D/A · Big-stake notice, amendedDec 4, 2024Big-stake noticeSEC
8-K · Current reportDec 2, 2024Material contractSEC
4/A · Change in ownership, amendedNov 26, 2024Insider tradeSEC
4 · Change in ownershipNov 18, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 12, 2024Quarterly reportSEC
8-K · Current reportNov 12, 2024ResultsSEC
8-K · Current reportSep 27, 2024Current reportSEC
10-Q · Quarterly reportAug 6, 2024Quarterly reportSEC
8-K · Current reportAug 6, 2024ResultsSEC
4 · Change in ownershipAug 5, 2024Insider tradeSEC
4 · Change in ownershipJul 31, 2024Insider tradeSEC
144 · Notice of proposed saleJul 30, 2024Other filingsSEC
144 · Notice of proposed saleJul 29, 2024Other filingsSEC
4 · Change in ownershipJul 12, 2024Insider tradeSEC

This page holds 200 of 566 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Olema Pharmaceuticals, Inc.’s releases · as of Nov 5, 2026

Common shares
87,606,263
Fully diluted
87,606,263

Fully diluted

LineSharesAs of
Common shares87,606,263Nov 5, 2026

Share count over time

CountShares
Nov 5, 202687,606,263

Open Cap table

Shareholders

Institutions

HolderSharesValueChange vs Jun 30Filed
Fidelity11.4MUS$98.9M−694KNov 10, 2026
Paradigm Biocapital Advisors LP8.72MUS$75.3M+50,000Nov 16, 2026
BlackRock7.18MUS$62M+467KNov 13, 2026
Bain Capital Life Sciences Investors, LLC7.09MUS$61.2MNo changeNov 16, 2026
Janus Henderson6.32MUS$54.6MFirst reportNov 16, 2026
Vanguard5.42MUS$46.9M−63,952Nov 13, 2026
Bvf Inc5.3MUS$45.8MNo changeNov 16, 2026
Siren, L.L.C.4.86MUS$42MNo changeNov 12, 2026
State Street3.85MUS$33.2M−469KNov 12, 2026
Logos Global Management LP3.21MUS$27.7MNo changeNov 19, 2026
Show 50 holders
HolderSharesValueChange vs Jun 30Filed
Morgan Stanley2.38MUS$20.6M+546KNov 13, 2026
Franklin Templeton2.27MUS$17.1M−83,682Nov 12, 2026
Deep Track Capital, LP2.11MUS$18.2M+610KNov 16, 2026
Geode Capital1.97MUS$17M+151KNov 6, 2026
Cormorant Asset Management, LP1.75MUS$15.1M−400KNov 16, 2026
Dimensional1.55MUS$13.4M+136KNov 4, 2026
Goldman Sachs1.49MUS$12.8M−82,860Nov 16, 2026
Defilade Capital Management, L.P.1.44MUS$12.4M+515KNov 16, 2026
Lightspeed Management Company, L.L.C.1.36MUS$11.7MNo changeNov 13, 2026
Kingdon Capital Management, L.L.C.1.2MUS$10.4MNo changeNov 16, 2026
Candriam S.C.A.1.18MUS$10.3M+433KNov 3, 2026
Ameriprise1.15MUS$9.97M+313KNov 16, 2026
Duquesne Family Office LLC987KUS$8.53MNo changeNov 16, 2026
Point72 Asset Management, L.P.911KUS$7.87M−160KNov 16, 2026
Qube Research & Technologies Ltd819KUS$7.08M+156KNov 13, 2026
Hudson Bay Capital Management LP700KUS$6.05M+134KNov 13, 2026
Northern Trust692KUS$5.98M+17,552Nov 16, 2026
Schwab672KUS$5.81M+154KNov 16, 2026
Vivo Capital, LLC672KUS$5.8MNo changeNov 13, 2026
Two Sigma661KUS$5.71M−471KNov 16, 2026
Algert Global LLC631KUS$5.45M+550KNov 17, 2026
Woodline Partners LP588KUS$5.08M−163KNov 16, 2026
Perceptive Advisors LLC575KUS$4.97MNewNov 16, 2026
Citadel554KUS$4.79M−87,926Nov 16, 2026
Hrt Financial LP500KUS$4.32MNewNov 13, 2026
Pier Capital, LLC488KUS$4.22M+267KNov 13, 2026
Bank of America449KUS$3.88M+114KNov 16, 2026
Susquehanna431KUS$3.72M+103KNov 16, 2026
Hennion & Walsh Asset Management, Inc.421KUS$3.64M+850Oct 13, 2026
Vestal Point Capital, LP420KUS$3.63M+1,449Nov 16, 2026
Rock Springs Capital Management LP384KUS$3.31M+148KNov 16, 2026
Ikarian Capital, LLC383KUS$3.31MNo changeNov 16, 2026
UBS353KUS$3.05M+81,173Nov 16, 2026
Trexquant Investment LP342KUS$2.96M+250KNov 16, 2026
SEB Asset Management AB339KUS$2.93MNo changeNov 4, 2026
Fisher Asset Management, LLC332KUS$2.87M+35,694Nov 6, 2026
Wellington275KUS$2.38M−251KNov 16, 2026
BNY223KUS$1.92M+448Nov 5, 2026
Jones Hill Capital LP206KUS$1.78M−368KNov 13, 2026
Squarepoint Ops LLC199KUS$1.72M−417KNov 9, 2026

This page holds 50 of 170 holders. Open Shareholders

Funds

HolderSharesValueChangeAs of
State Street(R) SPDR(R) S&P(R) Biotech ETF2.72MUS$34M+245KJun 30, 2026
Vanguard Total Stock Market Index Fund2.61MUS$32.7M+184KJun 30, 2026
iShares Russell 2000 ETF2.05MUS$25.6M+346KJun 30, 2026
Select Health Care Portfolio1.5MUS$19.8M+150KMay 31, 2026
Strategic Advisers Fidelity U.S. Total Stock Fund1.13MUS$14.9M+127KMay 31, 2026
Fidelity Stock Selector Small Cap Fund907KUS$10.4M+168KJul 31, 2026
Fidelity Small Cap Index Fund856KUS$9.81M+165KJul 31, 2026
Fidelity Advisor Health Care Fund820KUS$9.39M+70,000Jul 31, 2026
Fidelity Advisor Biotechnology Fund777KUS$8.9MNo changeJul 31, 2026
Franklin Small Cap Growth Fund694KUS$7.94M+311KJul 31, 2026
Show 50 holders
HolderSharesValueChangeAs of
PGIM Jennison Health Sciences Fund663KUS$8.74M+318KMay 29, 2026
Janus Henderson Global Life Sciences Fund658KUS$8.23M−11,129Jun 30, 2026
Vanguard Extended Market Index Fund652KUS$8.16M+71,775Jun 30, 2026
Select Biotechnology Portfolio628KUS$8.28M−65,000May 31, 2026
iShares Russell 2000 Value ETF613KUS$7.66M+15,140Jun 30, 2026
T. Rowe Price Health Sciences Fund, Inc.584KUS$7.3M−65,564Jun 30, 2026
Franklin Biotechnology Discovery Fund569KUS$6.51M+189KJul 31, 2026
Vanguard Explorer Fund558KUS$6.39MNewJul 31, 2026
Columbia Small Cap Value Discovery Fund546KUS$6.25MNewJul 31, 2026
Fidelity Series Small Cap Opportunities Fund521KUS$5.96M+2,500Jul 31, 2026
Fidelity U.S. Equity Central Fund520KUS$6.51M+20,000Jun 30, 2026
iShares Biotechnology ETF498KUS$6.23M+40,573Jun 30, 2026
Fidelity Small Cap Discovery Fund490KUS$5.61M+279KJul 31, 2026
Fidelity Series Small Cap Discovery Fund419KUS$4.8M+217KJul 31, 2026
Fidelity Series Small Cap Core Fund406KUS$4.64M+174KJul 31, 2026
Fidelity Small Cap Growth Fund388KUS$4.44MNo changeJul 31, 2026
Fidelity Enhanced Small Cap Core ETF371KUS$4.64M+335KJun 30, 2026
Vanguard Russell 2000 Index Fund359KUS$4.73M+63,791May 31, 2026
U.S. Small Cap Portfolio308KUS$3.53M+57,584Jul 31, 2026
Janus Henderson Venture Fund308KUS$3.85M+10,632Jun 30, 2026
VIP Health Care Portfolio285KUS$3.57M+20,000Jun 30, 2026
Fidelity Extended Market Index Fund269KUS$3.55M+58,077May 31, 2026
iShares Micro-Cap ETF262KUS$3.28M+86,162Jun 30, 2026
Victory Science & Technology Fund255KUS$2.92MNo changeJul 31, 2026
Schwab U.S. Small-Cap ETF247KUS$3.26M+51,626May 31, 2026
U.S. Micro Cap Portfolio235KUS$2.69M+3,887Jul 31, 2026
Dimensional U.S. Small Cap ETF234KUS$2.68M−50,451Jul 31, 2026
Fidelity Small Cap Growth K6 Fund193KUS$2.21MNo changeJul 31, 2026
Schwab Small-Cap Index Fund190KUS$2.18M+36,798Jul 31, 2026
Dimensional U.S. Core Equity 2 ETF186KUS$2.13M+110KJul 31, 2026
Fidelity Small Cap Stock Fund163KUS$1.87M+61,100Jul 31, 2026
Master Small Cap Index Series147KUS$1.83M+33,041Jun 30, 2026
Vanguard U.S. Momentum Factor ETF145KUS$1.91M+67,640May 31, 2026
Fidelity Advisor Small Cap Fund136KUS$1.79MNo changeMay 31, 2026
iShares Russell 2000 Growth ETF124KUS$1.55MNewJun 30, 2026
BlackRock Advantage Small Cap Core Fund124KUS$1.64M−1,533May 29, 2026
Vanguard Health Care Index Fund113KUS$1.49M−952May 31, 2026
VIP Stock Selector Portfolio110KUS$1.38M+10,000Jun 30, 2026
Small Company Growth Portfolio106KUS$1.32MNewJun 30, 2026
Nuveen Small Cap Blend Index Fund104KUS$1.19M+20,213Jul 31, 2026

This page holds 50 of 215 holders. Open Shareholders

Insider trades

InsiderTradeSharesPriceValueDate
Harmon Cyrus
Director
Sale12,500USD 11.71US$146KJul 24, 2026
Harmon Cyrus
Director
Sale12,500USD 11.58US$145KJul 23, 2026

Big stakes

HolderStakeSharesDate
FMR LLC13.80%12.1MJun 30, 2026
Paradigm Biocapital Advisors LP9.99%7.43MDec 31, 2024
BVF PARTNERS L P/IL9.80%8.94MOct 14, 2026
Bain Capital Life Sciences Opportunities IV, L.P.8.15%7.47MMar 31, 2026
Janus Henderson Group PLC7.20%6.32MSep 30, 2026
BlackRock, Inc.7.10%6.24MJun 30, 2026
Raymond Debbane5.10%4.46MMar 16, 2026
Logos Global Management LP4.70%3.21MMar 18, 2025

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Bihua Chen
Other companies: BlossomHill Therapeutics, Inc. (Board Member · Since at least Aug 6, 2026); Helix Acquisition Corp. III (Chairperson and CEO, Director · Since at least Jan 22, 2026); BridgeBio Oncology Therapeutics, Inc. (Director · Since at least Feb 8, 2024); Biomea Fusion, Inc. (Director · Since at least Apr 15, 2021); Erasca, Inc. (Director · Jul 15, 2021 – Jun 22, 2023 · Past); Monte Rosa Therapeutics, Inc. (Director · Jun 23, 2021 – Jun 23, 2021 · Past); Verve Therapeutics Inc (Director · Jun 16, 2021 – Jun 21, 2021 · Past); Rain Oncology Inc (Director · Apr 22, 2021 – Apr 27, 2021 · Past); Design Therapeutics, Inc. (Director · Mar 25, 2021 – Mar 25, 2021 · Past); Prometheus Biosciences Inc (Director · Mar 11, 2021 – Mar 11, 2021 · Past); BioAtla, Inc. (Director · Dec 15, 2020 – Dec 18, 2020 · Past); Atea Pharmaceuticals, Inc. (Director · Oct 29, 2020 – Nov 3, 2020 · Past); MoonLake Immunotherapeutics (CEO and Chairman, Director · Oct 19, 2020 – Oct 22, 2020 · Past); Akouos Inc (Director · Jun 25, 2020 – Jun 30, 2020 · Past); Avidity Biosciences, Inc (Director · Jun 11, 2020 – Jun 16, 2020 · Past); Turning Point Therapeutics Inc (Director · Apr 16, 2019 – Aug 12, 2019 · Past); Axonics Modulation Technologies Inc (Director · Oct 30, 2018 – Oct 31, 2018 · Past); Constellation Pharmaceuticals Inc (Director · Jul 18, 2018 – Jul 18, 2018 · Past); Kezar Life Sciences, Inc. (Director · Jun 20, 2018 – Jun 25, 2018 · Past); Kiniksa Pharmaceuticals International, plc (Director · May 23, 2018 – May 29, 2018 · Past); Apellis Pharmaceuticals, Inc. (Director · Nov 8, 2017 – Nov 13, 2017 · Past); Kineta Inc. (Director · Nov 3, 2016 – Dec 14, 2017 · Past); Clearside Biomedical Inc (Director · Jun 1, 2016 – Jun 1, 2016 · Past); Cellectar Biosciences, Inc. (Director · Aug 15, 2014 – Aug 15, 2014 · Past)
Director · Nov 18, 2020 – Nov 23, 2020 · Past
Ian T. Clark
Other companies: Takeda Pharmaceutical Co. Ltd. (Director · Since at least Mar 18, 2026); BioMarin Pharmaceutical Inc. (Chair of the Board, · Since at least Aug 1, 2025); GoodRx Holdings, Inc. (Director · Since at least Jul 8, 2024); Kyverna Therapeutics, Inc. (Independent Director · Since at least Feb 7, 2024); Guardant Health, Inc. (Director · Since at least Oct 3, 2018); Corvus Pharmaceuticals, Inc. (Director · Since at least Jan 3, 2017); Forty Seven Inc (Director · Jun 27, 2018 – Apr 7, 2020 · Past); Tectonic Therapeutic, Inc. (Director · Jun 20, 2018 – Jun 6, 2023 · Past); Kite Pharma Inc (Director · Jan 3, 2017 – Oct 3, 2017 · Past); Agios Pharmaceuticals, Inc. (Director · Dec 30, 2016 – May 20, 2022 · Past); Terravia Holdings Inc (Director · May 26, 2011 – May 22, 2017 · Past); Dendreon Corp (Director · Oct 7, 2009 – Aug 20, 2010 · Past); Genentech Inc (EVP-COMMERCIAL · Sep 20, 2006 – Mar 26, 2009 · Past)
Director · Since at least Aug 12, 2020
Scott Garland
Other companies: Enliven Therapeutics, Inc. (Member of the Board of Directors · Since at least Jan 7, 2026); LB Pharmaceuticals Inc (Chairman of the Board, LB Pharmaceuticals · Since at least Sep 10, 2025); ALX Oncology Holdings Inc. (Chairman · Since at least Nov 28, 2022); Day One Biopharmaceuticals Inc (Director · Since at least Aug 16, 2021); Calithera Biosciences, Inc. (Director · Jul 10, 2020 – Jun 1, 2022 · Past); Portola Pharmaceuticals Inc (President and CEO, Director · Oct 8, 2018 – Jul 2, 2020 · Past); Karyopharm Therapeutics Inc. (Director · Nov 3, 2014 – Jun 6, 2019 · Past); Relypsa Inc (SVP & Chief Commercial Officer · Oct 31, 2014 – Sep 1, 2016 · Past); Exelixis, Inc. (EVP & Chief Commerical Officer · Oct 20, 2011 – Sep 18, 2013 · Past)
Director · Since at least Oct 16, 2023
Mark N Lampert
Other companies: Immunic, Inc. (Director · Since at least Feb 17, 2026); Kymera Therapeutics, Inc. (Director · Since at least Jan 11, 2023); MoonLake Immunotherapeutics (Director · Since at least Apr 5, 2022); Rain Oncology Inc (Director · Nov 8, 2022 – Jan 25, 2024 · Past); CTi Biopharma Corp (Director · Aug 9, 2022 – Jun 26, 2023 · Past)
Director · Since at least Jun 10, 2022
Sandra J. Horning
Other companies: Revolution Medicines, Inc. (Director · Since at least Nov 9, 2023); Moderna, Inc. (Director · Since at least Apr 29, 2020); Gilead Sciences, Inc. (Director · Since at least Jan 28, 2020); EQRx Inc (Director · Dec 17, 2021 – Nov 9, 2023 · Past); Foundation Medicine Inc (Director · Apr 7, 2015 – Apr 7, 2015 · Past)
Director · Since at least Nov 18, 2020
Cynthia M. Butitta
Other companies: Autolus Therapeutics plc (Chair of the Compensation Committee, Member of the Audit Committee · Since at least Mar 18, 2026); Century Therapeutics, Inc. (Director · Since at least Jun 17, 2021); UroGen Pharma Ltd. (of the Audit Committee · Since at least Jan 1, 2019); Kite Pharma Inc (Chief Operating Officer · Jun 19, 2014 – Oct 3, 2017 · Past)
Director · Since at least Aug 12, 2020
Frank McCormick
Other companies: BridgeBio Oncology Therapeutics, Inc. (Director · Since at least Aug 11, 2025); BridgeBio Pharma, Inc. (Director · Since at least Jun 27, 2019); Aduro Biotech Inc (Director · Apr 14, 2015 – Jun 6, 2018 · Past); Exelixis, Inc. (Director · May 2, 2006 – Dec 6, 2013 · Past)
Director · Sep 18, 2020 – Nov 23, 2020 · Past
John Moriarty
Other companies: Kardigan, Inc. (Chief Legal Officer and Corporate Secretary · Since at least Jun 17, 2026); Avidity Biosciences, Inc (Chief Legal Officer · Since at least Aug 1, 2024); Portola Pharmaceuticals Inc (EVP, General Counsel · Mar 12, 2018 – Jul 2, 2020 · Past); Alexion Pharmaceuticals Inc (EVP & General Counsel · Dec 10, 2012 – Feb 6, 2018 · Past)
EVP, Ch. Legal Officer & Sec. · Sep 19, 2020 – Feb 1, 2023 · Past
G Walmsley Graham
Other companies: Akero Therapeutics Inc (Director · Since at least Jun 19, 2019); LifeSci Acquisition II Corp (Director · Nov 20, 2020 – Nov 20, 2020 · Past); ALX Oncology Holdings Inc. (Director · Jul 16, 2020 – Jun 11, 2021 · Past)
Director · Since at least Jun 1, 2020
Gorjan Hrustanovic
Other companies: Kymera Therapeutics, Inc. (Director · Since at least Jun 16, 2021); Rain Oncology Inc (Director · Apr 22, 2021 – Jan 26, 2024 · Past)
Director · Since at least Nov 18, 2020
All 44 people
PersonSeat
Jason V. O'Byrne
Other companies: Vir Biotechnology, Inc. (EVP & Chief Financial Officer · Since at least Oct 2, 2024); Caribou Biosciences, Inc. (Chief Financial Officer · Jul 22, 2021 – Feb 20, 2024 · Past)
Chief Financial Officer · Since at least Aug 11, 2026
Shawnte M. Mitchell
Other companies: Zogenix Inc (EVP, GC & Secretary · Apr 20, 2020 – Mar 7, 2022 · Past); Aptevo Therapeutics Inc. (SVP, GC and Corporate Affairs · Aug 1, 2018 – Feb 18, 2020 · Past)
Chief Legal Officer and Corporate Secretary · Since at least Feb 18, 2025
Yi Larson
Other companies: RayzeBio, Inc. (Director · Sep 14, 2023 – Feb 26, 2024 · Past); Turning Point Therapeutics Inc (EVP & Chief Financial Officer · Aug 26, 2019 – Feb 8, 2021 · Past)
Director · Since at least Apr 5, 2021
Andrew Rappaport
Other companies: Atheros Communications Inc (Director · Feb 7, 2006 – May 24, 2011 · Past)
Director · Since at least Sep 18, 2020
Kinney Horn
Other companies: Immunome, Inc. (CHIEF BUSINESS OFFICER · Since at least Feb 12, 2024)
Chief Business Officer · Jun 10, 2020 – Feb 1, 2023 · Past
Prakash Raman
Other companies: Black Diamond Therapeutics, Inc. (CEO of InduPro, Inc. · Since at least Apr 10, 2024)
Director · Since at least Apr 28, 2026
Shane William Charles Kovacs
Other companies: PTC Therapeutics, Inc. (Chief Financial Officer · Sep 26, 2016 – May 9, 2017 · Past)
CH. OPERATING & FINANCIAL OFF. · Since at least Jun 15, 2020
Amoli PandyaVice President, Corporate Law · Since at least Nov 13, 2026
Angelos DovletoglouSenior Vice President, CMC and Supply Chain · Since at least Nov 5, 2026
Brad LanoueVice President, Market Access · Nov 4, 2026 – Nov 13, 2026 · Past
Courtney O'KonekVice President, Corporate Communications · Since at least Nov 3, 2026
Cyrus HarmonDirector · Since at least Jun 15, 2020
David C. MylesChief Scientific Officer · Since at least Jun 15, 2020
Ganesh WaghmareVice President, Drug Safety and Pharmacovigilance · Since at least Nov 5, 2026
Gopinath PalanisamyVice President, Pre-Clinical Pharmacology and Toxicology · Since at least Apr 25, 2025
James WagnerVice President, Legal Counsel · Since at least Nov 5, 2026
Julie DexterSenior Vice President, People and Culture · Since at least Nov 5, 2026
Kamesh KuchimanchiSenior Vice President, Regulatory Affairs · Since at least Nov 5, 2026
Karen PaeseVice President, Supply Chain · Since at least Nov 5, 2026
Kate SwearingenVice President, Program Management · Nov 4, 2026 – Nov 13, 2026 · Past
Kristin BrosofskyVice President, Clinical Operations · Since at least Nov 5, 2026
Margaret TondaVice President, Clinical Science · Since at least Nov 5, 2026
Mark ShilkrutSenior Vice President, Clinical Development · Since at least Nov 5, 2026
Meghna ChowdarySenior Vice President, Commercial Strategy and Operations · Since at least Nov 5, 2026
Naseem ZojwallaChief Medical Officer · Since at least Jan 31, 2022
Peter J KushnerCHIEF SCIENTIFIC OFFICER · Jun 15, 2020 – Feb 1, 2022 · Past
Rachel WeiVice President, Biostatistics · Since at least Nov 13, 2026
Radha IyerVice President, Quality Assurance · Since at least Nov 5, 2026
Richard HernandezSenior Vice President, Clinical Operations · Since at least Nov 5, 2026
Ronald E. SavageVice President, Clinical Pharmacology · Since at least Nov 5, 2026
Sasha AustinVice President, Finance and Controller · Nov 4, 2026 – Nov 13, 2026 · Past
Sasha Lu AustinVP of Finance and Controller · Since at least Jan 30, 2026
Sean P. BohenPresident and CEO · Since at least Sep 19, 2020
Yolande Du ToitVice President, Medical Affairs · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about Olema Pharmaceuticals, Inc.